IPCA Laboratories Ltd
NSE:IPCALAB
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
1 058.6
1 703.25
|
| Price Target |
|
We'll email you a reminder when the closing price reaches INR.
Choose the stock you wish to monitor with a price alert.
|
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Mastercard Inc
NYSE:MA
|
US |
|
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
|
Pfizer Inc
NYSE:PFE
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
|
Nike Inc
NYSE:NKE
|
US |
|
|
Visa Inc
NYSE:V
|
US |
|
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
|
3M Co
NYSE:MMM
|
US |
|
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
|
Coca-Cola Co
NYSE:KO
|
US |
|
|
Walmart Inc
NYSE:WMT
|
US |
|
|
Verizon Communications Inc
NYSE:VZ
|
US |
This alert will be permanently deleted.
IPCA Laboratories Ltd
IPCA Laboratories Ltd
Other Current Liabilities
IPCA Laboratories Ltd
Other Current Liabilities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Other Current Liabilities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
IPCA Laboratories Ltd
NSE:IPCALAB
|
Other Current Liabilities
₹6.7B
|
CAGR 3-Years
24%
|
CAGR 5-Years
16%
|
CAGR 10-Years
N/A
|
|
|
Dr Reddy's Laboratories Ltd
NSE:DRREDDY
|
Other Current Liabilities
₹57.8B
|
CAGR 3-Years
15%
|
CAGR 5-Years
10%
|
CAGR 10-Years
N/A
|
|
|
Cipla Ltd
NSE:CIPLA
|
Other Current Liabilities
₹25.4B
|
CAGR 3-Years
11%
|
CAGR 5-Years
8%
|
CAGR 10-Years
17%
|
|
|
Sun Pharmaceutical Industries Ltd
NSE:SUNPHARMA
|
Other Current Liabilities
₹93.2B
|
CAGR 3-Years
-1%
|
CAGR 5-Years
10%
|
CAGR 10-Years
15%
|
|
|
T
|
Torrent Pharmaceuticals Ltd
NSE:TORNTPHARM
|
Other Current Liabilities
₹10.1B
|
CAGR 3-Years
7%
|
CAGR 5-Years
12%
|
CAGR 10-Years
7%
|
|
|
M
|
Mankind Pharma Ltd
NSE:MANKIND
|
Other Current Liabilities
₹8.4B
|
CAGR 3-Years
22%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
IPCA Laboratories Ltd
Glance View
In the bustling corridors of the global pharmaceutical industry, IPCA Laboratories Ltd. stands as a formidable presence, deeply rooted in its commitment to innovative healthcare solutions. Established with a mission to enhance patient well-being, IPCA has grown from a modest formulation company in India into a multinational endeavor, celebrated for its prowess in the realms of Active Pharmaceutical Ingredients (APIs) and finished dosage forms. This vertically integrated company meticulously controls every element of its production chain, securing its position as a trusted supplier to some of the world's leading pharmaceutical giants. IPCA's robust portfolio includes a wide array of therapeutic segments, from antimalarials and analgesics to antihypertensives and nutraceuticals, showcasing its versatility and comprehensive grasp over diverse medical needs. What sets IPCA apart in the crowded pharmaceutical landscape is its strategic blend of cutting-edge research, efficient manufacturing practices, and a global distribution network. The company invests significantly in research and development, channeling innovation into its drug development processes to sustain its competitive edge. Enhanced production capabilities at its state-of-the-art facilities ensure that IPCA not only meets stringent international standards but also operates at optimal cost efficiency. This enables the company to leverage economies of scale, thereby maximizing profitability. By exporting to over 100 countries and employing a robust marketing strategy, IPCA ensures its products have a wide reach across developed and emerging markets. Thus, through its integrated approach to drug development and distribution, IPCA Laboratories continues to cultivate a steady stream of revenue while contributing substantially to global healthcare.
See Also
What is IPCA Laboratories Ltd's Other Current Liabilities?
Other Current Liabilities
6.7B
INR
Based on the financial report for Sep 30, 2024, IPCA Laboratories Ltd's Other Current Liabilities amounts to 6.7B INR.
What is IPCA Laboratories Ltd's Other Current Liabilities growth rate?
Other Current Liabilities CAGR 5Y
16%
Over the last year, the Other Current Liabilities growth was 6%. The average annual Other Current Liabilities growth rates for IPCA Laboratories Ltd have been 24% over the past three years , 16% over the past five years .
You don't have any saved screeners yet
